Meal timing may matter for new sickle cell drug
NCT ID NCT06433661
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This study looked at how a high-fat meal changes the amount of the drug etavopivat in the blood of 16 healthy adults. Participants took a single dose of etavopivat after eating a high-fat meal and on an empty stomach on separate days. The goal is to understand if food affects how the drug is absorbed, which can guide future dosing for people with sickle cell disease or thalassemia.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS SICKLE CELL DISEASE, THALASSEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ICON-Salt Lake City
Salt Lake City, Utah, 84124, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
etavopivat
What this could lead to
If successful, this study could help determine the best way to take etavopivat (with or without food) for future sickle cell disease and thalassemia treatments.
What could go wrong
This is a small, early-phase study in healthy volunteers, not patients. Results may not directly predict how the drug works in people with the disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.